Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
ZYPREXA 10 mg powder for solution for injection.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection. Yellow lyophilised powder. |
Each vial contains 10 mg olanzapine. After reconstitution each ml of the solution contains 5 mg olanzapine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Olanzapine |
Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Type I, 5 ml glass vial.
One carton contains 1 or 10 vial(s).
Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
EU/1/96/022/016 – ZYPREXA – Powder for solution for injection. 1 vial
EU/1/96/022/017 – ZYPREXA – Powder for solution for injection. 10 vials
Date of first authorisation: 27 September 1996
Date of latest renewal: 12 September 2006
| Drug | Countries | |
|---|---|---|
| ZYPREXA | Austria, Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
